Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in PS or ET patients and HV
Phase 3
- Conditions
- PS:Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy(PSP), ET
- Registration Number
- JPRN-jRCT2080221472
- Lead Sponsor
- ihon Medi-Physics Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
[HV]
- Healthy Japanese people.
[PD]
- Japanese patients clinically- diagnosed with PD.
[MSA]
- Japanese patients clinically- diagnosed with MSA.
[PSP]
- Japanese patients clinically- diagnosed with PSP.
[ET]
- Japanese patients clinically- diagnosed with ET.
Exclusion Criteria
-Patients clinically-diagnosed with dementia.
-Patients using following drugs: cocaine hydrochloride, mazindol, methylphenidate hydrochloride, sertraline hydrochloride.
-Patients with hepatic, renal or hematopoietic dysfunction.
-People with allergic reaction to alcohol or iodine.
-Women who are pregnant, lactating or possibly pregnant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy: diagnostic accuracy by reading committee<br>Safety: subjective/objective symptoms, vital signs, electrocardiogram, clinical tests
- Secondary Outcome Measures
Name Time Method